Holen Sie sich die Stockscreener-App
87.36
4.63%
-4.72
Schlusskurs vom Vortag:
$92.08
Offen:
$91.57
24-Stunden-Volumen:
105.10K
Relative Volume:
0.45
Marktkapitalisierung:
$1.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.95%
1M Leistung:
-12.42%
6M Leistung:
+128.51%
1J Leistung:
+576.04%
1-Tages-Spanne:
$86.08
$91.57
1-Wochen-Bereich:
$86.08
$99.72
52-Wochen-Spanne:
$12.10
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
353 W. LANCASTER AVENUE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
87.91 | 1.09B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Mizuho | Outperform |
| 2025-12-05 | Eingeleitet | BTIG Research | Buy |
| 2025-12-04 | Eingeleitet | Craig Hallum | Buy |
| 2025-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Published on: 2026-01-23 00:45:18 - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
FOMO Trade: Does RAIN stock benefit from AI growthQuarterly Profit Report & Short-Term High Return Ideas - baoquankhu1.vn
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from BTIG Research - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Palvella’s rare-disease pipeline gains momentum amid positive topline data - S&P Global
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Will Palvella Therapeutics Inc. (PI6) stock benefit from commodity supercycleForecast Cut & Proven Capital Preservation Methods - Улправда
A new gel that could become the first treatment for rare skin diseases - Stock Titan
Will Palvella Therapeutics Inc. stock maintain growth storyMarket Growth Summary & Low Drawdown Investment Ideas - Улправда
Palvella Therapeutics stock maintains Buy rating at TD Cowen ahead of key trial data - Investing.com Canada
Why analysts recommend Palvella Therapeutics Inc. (PI6) stockJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - Улправда
What is the fair value of Palvella Therapeutics Inc. stock now2025 Support & Resistance & Verified Technical Trade Signals - ulpravda.ru
Will Palvella Therapeutics Inc. stock pay special dividendsPortfolio Return Report & Low Risk High Reward Ideas - ulpravda.ru
BTIG Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Mizuho - Defense World
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo
Aug Swings: Will Palvella Therapeutics Inc stock maintain growth storyJuly 2025 Technicals & High Accuracy Buy Signal Tips - moha.gov.vn
Mizuho Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.5%Here's What Happened - MarketBeat
Palvella Therapeutics Appoints Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - citybiz
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - The Manila Times
Palvella Therapeutics Strengthens Leadership Team with - GlobeNewswire
Mizuho initiates coverage on Palvella Therapeutics stock with Outperform rating - Investing.com Canada
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Stock Watch: Biotech Acquisitions Drive Sector Momentum Going Into 2026 - Citeline News & Insights
Earnings Recap: Will Palvella Therapeutics Inc stock pay special dividendsEarnings Recap Report & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Palvella Therapeutics (NASDAQ:PVLA) Trading Down 4.9% – What’s Next? - Defense World
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):